Peerwise Medical, Corp.
Summary
Peerwise Medical, Corp., a Delaware corporation incorporated in 2023, has raised $5.0M in a Regulation D private placement as of May 20, 2026. The offering is classified under 'Other Technology' and involves equity securities, with no debt or pooled investment fund interests indicated. The filing lists Natalia Khosla and Rachel O'Driscoll as executive officers and directors, but does not disclose the number of investors, whether any are non-accredited, or the minimum investment accepted. The absence of an exemption rule (506(b) or 506(c)) in the provided XML excerpt limits further structural detail, but the $5.0M raise signals early-stage capital deployment in the healthcare technology space.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
Peerwise Medical, Corp., a Delaware corporation incorporated in 2023, has raised $5.0M in a Regulation D private placement as of May 20, 2026. The offering is classified under 'Other Technology' and involves equity securities, with no debt or pooled investment fund interests indicated. The filing lists Natalia Khosla and Rachel O'Driscoll as executive officers and directors, but does not disclose the number of investors, whether any are non-accredited, or the minimum investment accepted. The absence of an exemption rule (506(b) or 506(c)) in the provided XML excerpt limits further structural detail, but the $5.0M raise signals early-stage capital deployment in the healthcare technology space.
Investor Edge
Watch for an amended Form D (D/A) which would reveal changes in offering terms, additional investors, or a larger raise. Also monitor for any subsequent patent filings or FDA-related announcements from Peerwise Medical, as these would validate the technology and potentially attract strategic partners.
Sector capital positioning
This $5.0M raise in the 'Other Technology' sector reflects continued private capital flow into early-stage health-tech ventures, particularly those leveraging digital or platform-based models. The modest size suggests a seed or Series A round, aligning with current trends where investors are selectively backing capital-efficient startups in medical technology.
Convergence Signals
No direct convergence signals (patents, government contracts, or legislation) are evident from the filing. However, the company's New York address and incorporation in Delaware are standard for startups. The involvement of two female executives may align with broader diversity-focused investment trends, but this is speculative.
Key Takeaways
- Peerwise Medical raised $5.0M in private equity under Regulation D, with first sale on May 20, 2026.
- The filing lists Natalia Khosla and Rachel O'Driscoll as executive officers and directors, but no external investors are named.
- The 'Other Technology' classification and $5.0M amount suggest an early-stage health-tech company, likely pre-revenue.
Risk Indicators & Flags
The filing lacks critical details such as the specific exemption rule (506(b) or 506(c)), total number of investors, and whether any non-accredited investors participated. This opacity could indicate a small, insider-led round or incomplete disclosure. Additionally, the company is very young (incorporated in 2023), increasing execution risk.
Verification & References
All data is directly from the SEC Form D filing (Accession Number 000213791226000001). The company's CIK (0002137912) and EDGAR URL are provided. The $5.0M raised, date of first sale (2026-05-20), and officer/director names are verifiable. The exemption rule and investor count are not available in the provided excerpt.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Star Catcher Industries Inc.
Rely Intelligence, Inc.
Public Royalties Inc.
OpsCo, Inc.
PVI Co Inc.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Ushering in the Next Frontier of Quantum Innovation
This executive order updates the National Quantum Strategy and establishes a national effort (QC-ADDS) to develop a quantum computer for scientific discovery, with deployment at a Department of Energy facility. It directs multiple agencies to prioritize quantum sensing, networking, and supply chain initiatives, and mandates plans for commercial readiness and national security applications.
Securing the Nation Against Advanced Cryptographic Attacks
This executive order mandates a nationwide transition of federal information systems and critical infrastructure to post-quantum cryptography (PQC) by specific deadlines (2030 for key establishment, 2031 for digital signatures), directs NIST to lead technical guidance and a pilot project, requires agencies to appoint PQC migration leads, and orders the Federal Acquisition Regulatory Council to propose rules requiring contractors to comply with NIST PQC standards by 2030.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →